GWM
TEVA icon

Geneos Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Geneos Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
31,507
-2,650
-8% -$88.3K 0.02% 532
2026
Q1 		$1.03M Sell
34,157
-1,400
-4% -$45K 0.02% 507
2025
Q4 		$1.11M Sell
35,557
-500
-1% -$12.3K 0.03% 479
2025
Q3 		$728K Sell
36,057
-839
-2% -$14.7K 0.02% 562
2025
Q2 		$618K Buy
36,896
+2,349
+7% +$37.9K 0.02% 648
2025
Q1 		$531K Buy
34,547
+11,425
+49% +$204K 0.02% 601
2024
Q4 		$510K Sell
23,122
-19,400
-46% -$353K 0.02% 582
2024
Q3 		$766K Sell
42,522
-4,560
-10% -$79.8K 0.03% 459
2024
Q2 		$765K Buy
47,082
+100
+0.2% +$1.54K 0.03% 404
2024
Q1 		$663K Sell
46,982
-114
-0.2% -$1.44K 0.03% 429
2023
Q4 		$492K Sell
47,096
-3,000
-6% -$28K 0.02% 487
2023
Q3 		$511K Sell
50,096
-1,186
-2% -$11K 0.03% 458
2023
Q2 		$386K Buy
51,282
+200
+0.4% +$1.62K 0.02% 514
2023
Q1 		$452K Sell
51,082
-475
-0.9% -$4.7K 0.03% 464
2022
Q4 		$470K Sell
51,557
-3,100
-6% -$27K 0.03% 437
2022
Q3 		$441K Sell
54,657
-11,125
-17% -$98.4K 0.03% 420
2022
Q2 		$519K Sell
65,782
-6,200
-9% -$54K 0.03% 484
2022
Q1 		$675K Buy
71,982
+11,044
+18% +$92.2K 0.03% 465
2021
Q4 		$488K Buy
60,938
+6,133
+11% +$55.4K 0.02% 583
2021
Q3 		$531K Sell
54,805
-800
-1% -$7.49K 0.02% 546
2021
Q2 		$546K Sell
55,605
-5,381
-9% -$57K 0.02% 545
2021
Q1 		$652K Sell
60,986
-571
-0.9% -$6.55K 0.02% 564
2020
Q4 		$639K Buy
61,557
+14,650
+31% +$140K 0.03% 470
2020
Q3 		$409K Sell
46,907
-8,665
-16% -$91.7K 0.02% 483
2020
Q2 		$677K Buy
55,572
+9,550
+21% +$108K 0.04% 355
2020
Q1 		$347K Buy
46,022
+8,928
+24% +$91.5K 0.02% 454
2019
Q4 		$369K Buy
37,094
+2,550
+7% +$22.8K 0.02% 509
2019
Q3 		$239K Sell
34,544
-307
-0.9% -$2.35K 0.01% 591
2019
Q2 		$321K Buy
34,851
+1,320
+4% +$15.9K 0.02% 525
2019
Q1 		$525K Buy
33,531
+705
+2% +$12.4K 0.03% 386
2018
Q4 		$515K Sell
32,826
-1,950
-6% -$40K 0.04% 365
2018
Q3 		$749K Buy
34,776
+22,882
+192% +$531K 0.05% 311
2018
Q2 		$289K Sell
11,894
-9,957
-46% -$203K 0.02% 455
2018
Q1 		$373K Sell
21,851
-17,232
-44% -$336K 0.03% 367
2017
Q4 		$740K Sell
39,083
-1,075
-3% -$16.2K 0.07% 256
2017
Q3 		$706K Sell
40,158
-1,097
-3% -$24.7K 0.07% 244
2017
Q2 		$1.37M Buy
41,255
+11,885
+40% +$368K 0.14% 149
2017
Q1 		$942K Buy
29,370
+3,434
+13% +$117K 0.1% 182
2016
Q4 		$940K Buy
25,936
+19,085
+279% +$762K 0.12% 167
2016
Q3 		$315K Buy
6,851
+333
+5% +$17.4K 0.04% 346
2016
Q2 		$326K Sell
6,518
-317
-5% -$16.9K 0.05% 326
2016
Q1 		$370K Buy
+6,835
New +$401K 0.06% 294

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Geneos Wealth Management's TEVA Position: Q2 2026 in Review

Geneos Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 7.8% in Q2 2026, selling an estimated $88.3K and leaving 31,507 shares worth $1.07M. The position accounts for 0.02% of the portfolio, ranked #532.

Geneos Wealth Management first reported a position in TEVA in Q1 2016 and has held it in 42 quarters since. The position peaked at $1.37M in Q2 2017. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Geneos Wealth Management held 31,507 shares of Teva Pharmaceuticals worth $1.07M as of Q2 2026.
  • Geneos Wealth Management sold 2,650 Teva Pharmaceuticals shares in Q2 2026, an estimated $88.3K.
  • Teva Pharmaceuticals made up 0.02% of Geneos Wealth Management's portfolio in Q2 2026, its #532 holding.
  • Geneos Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2016 and has held it in 42 quarters since.
  • Geneos Wealth Management's Teva Pharmaceuticals position peaked at $1.37M in Q2 2017.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.